甲磺酸洛美他派(Lomitapide Mesylate) - 药物靶点：MTTP_在研适应症：II a型高脂蛋白血症，纯合子家族性高胆固醇血症，结直肠癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lojuxta、lomitapide、Lomitapide Mesilate

+ [7]

靶点

MTTP

作用机制

MTTP抑制剂(微粒体甘油三酯转运蛋白复合体抑制剂)

治疗领域

遗传病与畸形内分泌与代谢疾病其他疾病+ [2]

在研适应症

II a型高脂蛋白血症纯合子家族性高胆固醇血症结直肠癌

非在研适应症-

原研机构

Bristol Myers Squibb Co.

在研机构

Amryt Pharma Holdings Ltd.

CHIESI Farmaceutici SpARecordati Rare Diseases, Inc.

+ [2]

非在研机构

Aegerion Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2012-12-21),

纯合子家族性高胆固醇血症

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)、临床急需境外新药 (中国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C40H41F6N3O5S

InChIKeyQKVKOFVWUHNEBX-UHFFFAOYSA-N

CAS号202914-84-9

关联

22

项与甲磺酸洛美他派相关的临床试验

NCT04681170 / Completed临床3期

Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy

This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable LLT (including LA, when applicable) comprising of the following phases:
* Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks)
* Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks):
* Efficacy Phase (starting at Baseline, i.e. Day [D] 0 for 24 weeks±3 days
* Safety Phase (starting at Week 24±3 days for 80±1 weeks)

开始日期2020-12-14

申办/合作机构

Amryt Pharma Holdings Ltd.

EUCTR2019-002278-30-DE / Not yet recruiting临床3期

Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) on stable lipid-lowering therapy

开始日期2020-08-12

申办/合作机构

Amryt Pharmaceuticals DAC

EUCTR2018-002911-80-IT / Not yet recruiting临床3期IIT

Open-label study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome - LOCHNES

开始日期2018-12-18

申办/合作机构-

100 项与甲磺酸洛美他派相关的临床结果

登录后查看更多信息

100 项与甲磺酸洛美他派相关的转化医学

登录后查看更多信息

100 项与甲磺酸洛美他派相关的专利（医药）

登录后查看更多信息

217

项与甲磺酸洛美他派相关的文献（医药）

2024-12-01·Lancet Diabetes & Endocrinology

Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study

Article

作者: Masana, Luis ; Buonuomo, Paola Sabrina ; Maatouk, Faouzi ; Kholaif, Naji ; Löwe, Sandra ; Schmitt, Claus Peter ; Taylan, Christina ; Zambon, Alberto ; Cunningham, Tracy ; Driemeyer, Joenna ; Mangal, Brian ; Martinez-Hervas, Sergio ; Cohen, Hofit ; Al-Dubayee, Mohammed ; Alashwal, Abdullah ; Diaz-Diaz, José Luis

BACKGROUND:

Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder characterised by extremely high concentrations of LDL cholesterol, leading to early-onset atherosclerosis. Lomitapide is an orally administered microsomal triglyceride transfer protein (MTP) inhibitor that effectively lowers LDL cholesterol and is approved for adults with HoFH. We aimed to investigate the efficacy and safety of lomitapide in paediatric patients with HoFH receiving standard-of-care lipid-lowering therapy.

METHODS:

APH-19 is an open-label, single-arm, phase 3 trial performed at 12 study centres in Germany, Israel, Italy, Saudi Arabia, Spain, and Tunisia. A 6-week run-in period was followed by a 24-week efficacy phase and an 80-week safety phase. Patients aged 5-17 years, on stable lipid-lowering therapy, with HoFH diagnosed using the criteria from the 2014 European Atherosclerosis Society Consensus Panel on HoFH were titrated to maximum tolerated doses of oral lomitapide, starting at 2 mg (patients aged 5-15 years) or 5 mg (patients aged 16-17 years). The primary endpoint was the percentage change from baseline to week 24 in LDL cholesterol, which was assessed in patients who had received at least one dose of lomitapide, and who had a baseline and at least one post-baseline measurement. The secondary outcomes were the percentage change from baseline at week 24 in total cholesterol, non-HDL cholesterol, VLDL cholesterol, apolipoprotein B, triglycerides, and lipoprotein(a). Safety was assessed in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04681170.

FINDINGS:

Between Dec 20, 2020, and Oct 16, 2022, 43 patients were included and treated (24 [56%] were female and 19 [44%] were male, and median age was 10·7 years [7·0-14·0]). Mean change from baseline in LDL cholesterol at week 24 was -53·5% (95% CI -61·6 to -45·4, p<0·0001). Mean percentage reductions were observed at week 24 for non-HDL cholesterol (-53·9%, 95% CI -61·7 to -46·1, p<0·0001), total cholesterol (-50·0%, 95% CI -57·6 to -42·4, p<0·0001), VLDL cholesterol (-50·2%, -59·1 to -41·2, p<0·0001), apolipoprotein B (-52·4%, -60·3 to -44·5, p<0·0001), triglycerides was -49·9% (-58·8 to -41·0, p<0·0001), and lipoprotein(a) (-11·3%, -32·9 to 10·3 [in 21 patients with measurements in mg/dL]; -23·6%, -38·2 to -9·0 [in 22 patients with measurements in nmol/L]; p=0·0070 combined). Adverse events were mostly mild, and gastrointestinal and hepatic in nature. Adverse events of special interest were reported for five (12%) patients (gastrointestinal in two patients and hepatic in three). One serious treatment-emergent adverse event was reported (also classed as an adverse event of special interest): an increase in hepatic enzymes, resulting in two dose interruptions, two dose reductions, and a repeated dose escalation.

INTERPRETATION:

Lomitapide provided a significant, clinically meaningful LDL cholesterol reduction and has the potential to be an efficient, LDL receptor-independent option for paediatric patients with HoFH.

FUNDING:

Amryt Pharmaceuticals.

2024-12-01·MOLECULAR BIOLOGY REPORTS

Lomitapide: navigating cardiovascular challenges with innovative therapies

Review

作者: Ait-Aissa, Karima ; Sahyoun, Amal M ; Apu, Ehsanul Hoque ; Abidi, Ammaar H ; Kassan, Modar ; Kassan, Adam ; Munkhsaikhan, Undral

Dyslipidemia is the most significant risk factor for cardiovascular diseases (CVDs) Secondary dyslipidemia: its treatments and association with atherosclerosis. Glob Health Med, Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies. The current treatment strategies for managing dyslipidemia focus on reducing low-density lipoprotein cholesterol (LDL-C) to minimize the risks of atherosclerosis and myocardial infarction (MI). Homozygous Familial Hypercholesterolemia (HoFH) is an inherited autosomal dominant disease caused by a mutation in the LDL receptor (LDLr), which can lead to extremely high levels of LDL-C The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr(-/-) Mice with Obesity, The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity. Although statin therapy has been the primary treatment for dyslipidemia, HoFH patients do not respond well to statins, requiring alternative therapies. Microsomal triglyceride transfer protein (MTP) inhibition has emerged as a potential therapeutic target for treating HoFH. MTP is primarily responsible for transferring triglyceride and other lipids into apolipoprotein B (ApoB) during the assembly of very low-density lipoprotein (VLDL) particles in the liver. Lomitapide, an inhibitor of MTP, has been approved for treatingof HoFH adults. Unlike statins, lomitapide does not act on the LDLr to reduce cholesterol. Instead, lomitapide lowers the levels of ApoB-containing proteins, primarily VLDL, eventually decreasing LDL-C levels. Studies have shown that lomitapide can reduce LDL-C levels by more than 50% in patients with HoFH who have failed to respond adequately to other treatments. Lowering LDL-C levels is important for preventing atherosclerosis, reducing cardiovascular risk, improving endothelial function, and promoting overall cardiovascular health, especially for patients with HoFH Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. This review paper focuses on research findings regarding the therapeutic benefits of lomitapide, highlighting its effectiveness in lowering cholesterol levels and reducing the risk of CVDs The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity.

2024-12-01·Lancet Diabetes & Endocrinology

Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children

Article

作者: Hegele, Robert A ; Brunham, Liam R

36

项与甲磺酸洛美他派相关的新闻（医药）

2024-12-13

·CPHI制药在线

国产降脂新药突破：恒瑞SHR-1918 III期临床正式启动

关注并星标CPHI制药在线近日，恒瑞医药自主研发的降脂新药SHR-1918首次启动了III期临床试验，标志着这一创新药物在研发进程中迈出了关键一步。SHR-1918是一款针对血管生成素样蛋白3（ANGPTL3）的单克隆抗体，旨在通过抑制ANGPTL3的活性，有效降低血清中的甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）水平，为高脂血症患者提供新的治疗选择。 ANGPTL3单抗研发现状血管生成素样蛋白3（ANGPTL3）作为调节血脂代谢的重要因子，近年来在降脂药物研发中备受关注。ANGPTL3主要通过抑制脂蛋白脂肪酶（LPL）和内皮脂肪酶（EL）的活性，影响甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）的代谢，从而与动脉粥样硬化性心血管疾病的发生发展密切相关。因此，针对ANGPTL3的单克隆抗体药物研发成为降脂领域的一大热点。目前，全球在研的ANGPTL3单抗仅有四款，其中再生元的依维苏单抗（Evinacumab）在2021年获得美国FDA批准，成为全球首个针对ANGPTL3功能的治疗药物，用于纯合子型家族性高胆固醇血症（HoFH）的治疗。然而，该药物尚未在中国上市，国内患者仍面临治疗选择有限的困境。恒瑞医药在多年持续研发投入的基础上，围绕ANGPTL3靶点进行了深入研究。SHR-1918不仅能够有效抑制ANGPTL3的活性，降低血清中的TG和LDL-C水平，还具有良好的安全性和耐受性。与此同时，国内外众多制药企业也在积极布局ANGPTL3单抗药物的研发。然而，由于ANGPTL3靶点的复杂性和药物研发的高风险性，目前仅有少数几款药物进入临床试验阶段。恒瑞医药的SHR-1918作为国内首个进入III期临床的ANGPTL3单抗药物，不仅在国内市场上占据领先地位，也在全球降脂药物研发领域崭露头角。恒瑞SHR-1918作用机制和特点恒瑞SHR-1918作为一种全人源抗ANGPTL3单克隆抗体（IgG4亚型），其作用机制独特且效果显著。SHR-1918能够与ANGPTL3的氨基端结构结合，阻断ANGPTL3与脂蛋白脂肪酶（LPL）和内皮脂肪酶（EL）的相互作用，从而恢复LPL和EL的活性，达到降低循环中的甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇（HDL-C）的作用。SHR-1918特点主要体现在以下几个方面：首先，SHR-1918具有显著的降脂效果。临床前动物模型研究表明，SHR-1918在降低LDL-C和TG水平方面表现出强大的疗效，且降脂效果具有剂量依赖性。在健康受试者中的I期临床试验结果也显示，SHR-1918单次皮下注射后能够有效持久降低LDL-C和TG水平，且未出现严重不良事件。此外，SHR-1918还具有独特的给药方式和方便的剂型。SHR-1918采用皮下注射的给药方式，避免了口服药物可能带来的胃肠道不适和肝脏首过效应等问题。同时，SHR-1918的剂型为注射液，规格为0.15g/支，方便患者使用和携带。SHR-1918在研发过程中还展现出了与其他降脂药物的协同作用潜力。临床前研究表明，SHR-1918与他汀类药物等常用降脂药物联合使用时，能够进一步增强降脂效果。恒瑞SHR-1918 I期临床数据在 2024 欧洲心血管学会（ESC）年会上，SHR-1918 的 I 期临床研究结果令人瞩目。SHR-1918 在健康受试者中显示出了良好的耐受性和药代动力学特性。安全性方面，在 100 至 1200mg 剂量范围内，SHR-1918 表现出良好的耐受性，未出现严重不良事件或导致治疗中断的不良事件。这为后续的临床研究和应用提供了坚实的安全保障。药代动力学特性上，SHR-1918 皮下注射给药后，随着剂量的增加，血清中的药物浓度相应上升，具有缓慢吸收和消除的特性。药物达峰时间在 8.0 至 10.0 天内，药物半衰期时间在 29.4 至 53.5 天。这样的特性使得药物在体内能够持续发挥作用，为降低血脂水平提供了稳定的药物浓度。疗效方面，与安慰剂相比，SHR-1918 在降低血清 LDL-C 和 TG 水平方面表现出显著效果，并具有剂量依赖性。300mg 及以上剂量水平的 LDL-C 降低超过 30%，持续 64 天以上，最高达 49.1%；TG 降低超过 50%，持续 85 天以上，最高达 82.8%。恒瑞SHR-1918价值和意义恒瑞 SHR-1918 III 期临床正式启动，这是一项意义重大的研究。该研究为多中心、随机、双盲、安慰剂对照，旨在评估对纯合家族性高胆固醇血症患者的 LDL-C 的降低作用。此项研究设计严谨，通过对大量患者的随机分组，确保了结果的可靠性和科学性。主要终点明确，即关注第 12 周患者的 LDL-C 水平相比于基线的百分比变化。纯合家族性高胆固醇血症是一种罕见且严重的遗传性疾病，患者由于低密度脂蛋白胆固醇受体的缺陷或缺失，导致 LDL-C 在血液中积累，增加心脏病和卒中的风险。目前可用的治疗选择虽然有多种，包括他汀类药物、依折麦布、洛美他派、米泊美生、PCSK9 单抗和 evinacumab 等，但许多患者仍难以达到理想的血脂控制水平。恒瑞 SHR-1918 的 III 期临床研究，为这些患者带来了新的希望。作为中国首个且唯一进入 III 期临床的 ANGPTL3 靶向药物，SHR-1918 有望在降脂领域取得重大突破。其通过抑制 ANGPTL3 的活性，降低血清中的甘油三酯和 LDL-C 水平，在前期的研究中已经展现出了良好的耐受性和药代动力学特性，以及显著的降脂效果。结语相信随着 III 期临床研究的深入开展，SHR-1918 将为高脂血症患者提供更有效的治疗手段，为我国降脂药物研发带来新的突破，也可能对整个降脂药物市场的格局产生重要影响。参考文献 1、恒瑞医药官方网站 END 【智药研习社近期直播】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床3期临床2期临床结果临床1期申请上市

2024-12-11

·echemi

Heng Rui Pharma Launches Phase III Trial for ANGPTL3 Monoclonal Antibody

According to information from the U.S. clinical trial registry Clinicaltrials on December 10, Chinese company Heng Rui Pharma has launched its first Phase III clinical trial (SHR-1918-301) for the ANGPTL3 monoclonal antibody SHR-1918. This drug marks the first domestic ANGPTL3 monoclonal antibody to enter the Phase III clinical trial stage. SHR-1918 is an ANGPTL3 monoclonal antibody developed by Heng Rui Pharma, which works by inhibiting ANGPTL3 activity to lower triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels in serum. LDL-C and TG are significant risk factors for the development of atherosclerotic cardiovascular diseases. ANGPTL3 plays a key role in lipid metabolism regulation by inhibiting lipoprotein lipase and endothelial lipase, thereby reducing the clearance of TG and LDL-C. In September this year, Heng Rui Pharma announced the results of its first Phase I study (SHR-1918-101) at the European Society of Cardiology (ESC) annual meeting. The study showed that SHR-1918 (100-1200mg, subcutaneously) demonstrated good tolerance and pharmacokinetic characteristics in healthy subjects, with a peak time of 8.0-10.0 days and a half-life of 29.4-53.5 days. Additionally, SHR-1918 effectively and durably reduced LDL-C and TG levels: patients receiving doses of SHR-1918 of 300mg or higher had LDL-C levels reduced by over 30% (up to 49.1%), lasting more than 64 days; TG levels were reduced by over 50% (up to 82.8%), lasting more than 85 days. Given the potential of SHR-1918 for treating rare dyslipidemia disorders, the drug received breakthrough therapy designation for homozygous familial hypercholesterolemia (HoFH) from the Chinese National Medical Products Administration (NMPA) in September. The launched Phase III study is a multicenter, randomized, double-blind, placebo-controlled clinical trial (n=45), aimed at evaluating the efficacy and safety of SHR-1918 in treating homozygous familial hypercholesterolemia (HoFH). The primary endpoint is the percentage change in LDL-C levels from baseline at week 12. Homozygous familial hypercholesterolemia (HoFH) is a rare and severe genetic disorder where patients accumulate LDL-C in the blood due to defects or deficiencies in low-density lipoprotein receptors (LDLR), increasing the risk of heart disease and stroke. Currently, available treatment options for these patients include statins (simvastatin, atorvastatin, and rosuvastatin), ezetimibe, lomitapide, mipomersen, PCSK9 monoclonal antibodies (evolocumab and alirocumab), and evinacumab. Among these, evinacumab (Regeneron/Ultragenyx) is the only marketed ANGPTL3 monoclonal antibody, with global sales of $80.9 million in 2023.

临床3期临床结果临床1期突破性疗法临床2期

2024-12-10

·医药魔方Info

恒瑞医药降血脂新药进入III期阶段

12月10日，美国临床试验收录网站Clinicaltrials显示，恒瑞医药启动了血管生成素样蛋白3（ANGPTL3）单抗SHR-1918的首个III期研究（SHR-1918-301）。该药物是首款进入III期阶段的国产ANGPTL3单抗。详情请点击阅读原文 SHR-1918是恒瑞医药自主研发的一款ANGPTL3单抗，通过抑制ANGPTL3的活性来降低血清中的甘油三酯（TG）水平和低密度脂蛋白胆固醇（LDL-C）水平。LDL-C和TG是动脉粥样硬化性心血管疾病发生发展的重要风险因素。ANGPTL3在调节脂质代谢中扮演着重要角色，能够通过抑制脂蛋白酶和内皮脂肪酶，减少TG和LDL-C的清除。恒瑞医药在今年9月举行的欧洲心血管学会（ESC）年会上公布了SHR-1918的首个I期研究（SHR-1918-101）结果。该研究结果表明，SHR-1918（100-1200mg，皮下注射）在健康受试者中显示出良好的耐受性和药代动力学特性（达峰时间：8.0-10.0天；半衰期：29.4-53.5天）。此外，SHR-1918能够有效且持久降低LDL-C水平和TG水平：与安慰剂组相比，300mg及以上剂量SHR-1918组患者的LDL-C水平降低超过30%（最高达49.1%），持续64天以上；TG水平降低超过50%（最高达82.8%），持续85天以上。鉴于SHR-1918对罕见血脂异常疾病的治疗潜力，该药物已在今年9月被CDE授予针对纯合子型家族性高胆固醇血症（HoFH）的突破性疗法资格。此次启动的III期研究是一项多中心、随机、双盲、安慰剂对照临床试验（n=45），旨在评估SHR-1918治疗纯合子型家族性高胆固醇血症（HoFH）的有效性和安全性。研究的主要终点为第12周患者的LDL-C水平相比于基线的百分比变化。纯合子型家族性高胆固醇血症（HoFH）是一种罕见且严重的遗传性疾病，患者由于低密度脂蛋白胆固醇受体（LDLR）的缺陷或缺失，导致LDL-C在血液中积累，从而增加心脏病和卒中的风险。目前，这类患者的可用治疗选择包括他汀类药物（辛伐他汀、阿托伐他汀和瑞舒伐他汀）、依折麦布、洛美他派、米泊美生、PCSK9单抗（依洛尤单抗和阿利西尤单抗）和evinacumab。其中，evinacumab（再生元/Ultragenyx）是唯一一款上市的ANGPTL3单抗，其2023年全球销售额为8090万美元。 Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线上直播 ↑点击扫码，直达直播间↑

突破性疗法临床3期临床结果

100 项与甲磺酸洛美他派相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09638	甲磺酸洛美他派	C10AX12	DB08827

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
II a型高脂蛋白血症	墨西哥	University of Pennsylvania	2014-02-09
纯合子家族性高胆固醇血症	美国	CHIESI Farmaceutici SpA	2012-12-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
II型高脂蛋白血症	临床3期	美国	Aegerion Pharmaceuticals, Inc.	2009-10-29
II型高脂蛋白血症	临床3期	加拿大	Aegerion Pharmaceuticals, Inc.	2009-10-29
II型高脂蛋白血症	临床3期	意大利	Aegerion Pharmaceuticals, Inc.	2009-10-29
II型高脂蛋白血症	临床3期	南非	Aegerion Pharmaceuticals, Inc.	2009-10-29
高脂血症	临床2期	美国	Aegerion Pharmaceuticals, Inc.	2007-10-01
高胆固醇血症	临床2期	美国	Aegerion Pharmaceuticals, Inc.	2007-04-01
结直肠癌	临床前	韩国	Ersteq Co., Ltd.	2022-12-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EUCTR2018-002911-80-IT (LOCHNES, Pubmed) 人工标引	临床3期	家族性乳糜微粒血症综合征	18	lomitapide	齋積淵選鹽窪構憲糧憲(鬱淵壓鹹築鬱簾膚網簾) = 積壓簾選願範遞膚鹹齋築餘餘築艱衊築艱簾積 (願憲鏇積獵鑰餘醖願糧 )	积极	2022-09-10
ESC2019	N/A	纯合子家族性高胆固醇血症	12	Lomitapide	襯選鹽願顧衊繭膚構廠(選衊構襯夢窪繭齋蓋願) = Two patients stopped lomitapide due to diet and alcohol restrictions 淵廠構蓋鑰鏇願淵繭積 (衊餘選繭衊簾製鹹蓋壓 ) 更多	-	2019-09-03
				LL drugs + lipoprotein apheresis
NCT00943306 (CTgov)	临床3期	纯合子家族性高胆固醇血症 \| II型高脂蛋白血症	19	lomitapide	選簾觸壓鏇構築願製齋(構製膚鏇糧艱鹽網遞鏇) = 襯遞蓋衊壓選鬱襯顧簾鹽築齋襯願築築衊淵鏇 (齋鬱醖獵繭鹹鏇蓋襯糧, 鑰築鬱膚淵繭廠鹽選網 ~ 鬱顧鏇齋齋壓選襯鏇齋) 更多	-	2018-05-11
NCT02044419 (CTgov)	临床1期	-	32	Lomitapide (Lomitapide Sprinkled in Applesauce (Treatment A))	製鹹壓憲廠繭範範選簾(積夢鏇憲膚繭襯製膚網) = 範繭製艱糧簾鏇鬱鹽鹹糧鹹觸網醖膚糧淵獵艱 (構餘淵顧獵鹹繭鬱鏇遞, 廠願繭構壓築網繭夢鹹 ~ 網齋窪鹹鏇繭夢廠鬱蓋) 更多	-	2018-02-13
				Lomitapide (Lomitapide Sprinkled in Mashed Banana (Treatment B))	製鹹壓憲廠繭範範選簾(積夢鏇憲膚繭襯製膚網) = 觸願製範艱憲餘鑰襯餘糧鹹觸網醖膚糧淵獵艱 (構餘淵顧獵鹹繭鬱鏇遞, 窪廠積築顧鏇鹽築憲觸 ~ 願鬱鹹築廠積積齋廠廠) 更多
NCT00730236 (Phase 3, Pubmed \| Atherosclerosis)	临床3期	纯合子家族性高胆固醇血症	29	Lomitapide	積願餘繭餘壓鹹鏇鬱製(淵積糧鹽艱網鬱積觸窪) = 選鬱憲憲積簾繭廠醖願糧膚鏇願願網糧選選鏇 (鏇鑰獵糧簾襯醖觸顧鏇 )	积极	2015-06-01
				lomitapide (Lipoprotein apheresis)	積願餘繭餘壓鹹鏇鬱製(淵積糧鹽艱網鬱積觸窪) = 鹽鑰餘顧顧夢衊構蓋構糧膚鏇願願網糧選選鏇 (鏇鑰獵糧簾襯醖觸顧鏇 )
NCT00690443 (CTgov)	临床2期	高胆固醇血症	44	Atorvastatin (Atorvastatin 20 mg)	積衊艱顧鹹餘鑰簾獵艱(簾製簾餘淵窪壓鏇願鏇) = 蓋繭選顧鑰遞醖觸壓壓醖齋築顧糧壓鏇衊壓蓋 (鹽繭蓋壓築範壓範鏇餘, 蓋簾窪鑰構餘鹽繭鏇壓 ~ 繭範憲淵鏇繭構窪齋顧) 更多	-	2013-02-25
				Atorvastatin+Lomitapide (Atorvastatin 20 mg + Lomitapide)	積衊艱顧鹹餘鑰簾獵艱(簾製簾餘淵窪壓鏇願鏇) = 簾鹽衊選糧餘網鑰鏇膚醖齋築顧糧壓鏇衊壓蓋 (鹽繭蓋壓築範壓範鏇餘, 範醖鏇範鹹醖網廠鹹觸 ~ 鹹遞顧網鏇願廠鏇簾壓) 更多
NCT01556906 (CTgov)	临床2期	纯合子家族性高胆固醇血症	6	Lomitapide	網鬱壓蓋衊製襯鑰淵醖(構鹽構範範積範選簾膚) = 範糧餘鹽窪網餘積壓簾膚鏇鹹製鹽艱鑰餘衊構 (繭網遞築觸壓構齋膚廠, 糧醖艱積繭壓齋膚窪衊 ~ 構鏇遞廠範糧鹹襯鹹觸) 更多	-	2013-02-22
NCT00730236 (Phase 3, CTgov)	临床3期	纯合子家族性高胆固醇血症	29	Lomitapide	獵鏇壓選鹹鑰網艱鹹鏇(齋鏇網淵獵願鹽簾範窪) = 範淵憲糧淵淵鑰築顧衊獵衊壓醖選構餘積範獵 (淵糧築鹹鹹繭鏇醖鏇膚, 顧鏇選壓糧願構願壓襯 ~ 鑰鏇積艱憲願醖糧構鬱) 更多	-	2013-02-22
NCT00559962 (CTgov)	临床2期	高脂血症	260	placebo (Placebo)	夢夢觸淵壓壓築壓鏇蓋(齋遞膚糧鹹膚糧鏇願範) = 蓋衊遞積廠艱窪網鹹網願選顧壓繭製選築製夢 (夢構餘鏇鹹獵鏇觸繭願, 憲膚網艱積襯襯遞觸艱 ~ 積齋襯鬱鏇簾範繭構艱) 更多	-	2013-02-22
				AEGR-733 (AEGR-733 5 mg)	夢夢觸淵壓壓築壓鏇蓋(齋遞膚糧鹹膚糧鏇願範) = 窪窪鑰艱構鹽鬱鬱襯製願選顧壓繭製選築製夢 (夢構餘鏇鹹獵鏇觸繭願, 製積鹽膚壓遞簾網構網 ~ 範廠鹹積鹽顧衊鏇鏇襯) 更多